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Abstract 
The DNA of all living cells undergoes continuous structural and chemical alteration, which may 
be derived from exogenous sources, or endogenous, metabolic pathways, such as cellular 
respiration, replication and DNA demethylation. It has been estimated that approximately 70,000 
DNA lesions may be generated per day in a single cell, and this has been linked to a wide variety 
of diseases, including cancer. However, it is puzzling why potentially mutagenic DNA 
modifications, occurring at a similar level in different organs/tissue, may lead to organ/tissue 
specific cancers, or indeed non-malignant disease – what is the basis for this differential 
response? We suggest that it is perhaps the precise location of damage, within the genome, that 
is a key factor. Finally, we draw attention to the requirement for reliable methods for 
identification and quantification of DNA adducts/modifications, and stress the need for these 
assays to be fully validated. Once these prerequisites are satisfied, DNA modification 
measurements, may be helpful as a clinical parameter for treatment monitoring, risk group 
identification and development of prevention strategies. 
 
Keywords: DNA damage, DNA repair, biomarkers, methylation, oxidative stress, 8-oxo-7,8-
dihydroguanine; 5-hydroxymethylcytosine; 5-formylcytosine; 5-carboxycytosine; 5-
hydroxymethyluracil; cancer;  
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1. Introduction 
The DNA of all living cells undergoes continuous structural and chemical alteration 
which, in part, occurs as a consequence of fundamental metabolic pathways, such as cellular 
respiration, replication and DNA demethylation. Generally, these alterations result in subtle 
modifications of the DNA structure, such as the addition of an oxygen, or methyl group. 
However, the modified nucleobase may have profound functional consequences for the cell. 
Cellular respiration is a source of reactive oxygen species1 (ROS), as is a wide variety of 
environmental insults, such as ionizing or ultraviolet radiation, and exposure to certain chemicals. 
These ROS lead to the continual modification of cellular DNA, both nuclear and mitochondrial. 
8-Oxo-7,8-dihydroguanine (8-oxoGua; this is increasingly the preferred nomenclature, see 
Cooke et al. for the rationale [1], Figure 1), is one of a number of oxidatively modified DNA 
nucleobases and its measurement is widely used as a biomarker of oxidative stress. It is also the 
most studied ROS-derived, DNA damage product, and is often used as a primary example to 
illustrate how oxidatively generated lesions may exert their pathological effects.  
During replication Ura, a canonical base of RNA, may be inserted into DNA, instead of 
Thy, resulting in Ura:Ade mispairing. It may also arise as a consequence of spontaneous 
deamination of Cyt (leading to Ura:Gua mispairing). Ura:Gua mis-pairs are mutagenic and may 
lead to C→T transitions. In contrast Ura:Ade base-pairs are not directly mutagenic, however, 
they may be cytotoxic, and their presence may lead to mutations when Ura is excised by uracil-
DNA glycosylases (UNGs) with the resultant formation of an abasic site. 
DNA methylation is involved in a range of diverse biological processes, including gene 
expression which, in turn, has a profound impact on cellular identity and organismal fate [2]. 
                                                          
1Abbreviations: reactive oxygen species, ROS; 8-oxo-7,8-dihydroguanine, 8-oxoGua; uracil-
DNA glycosylase, UNG; ten-eleven translocation protein, TET; 5-methylcytosine, 5-mCyt; 5-
hydroxymethylcytosine, 5-hmCyt; 5-formylcytosine, 5-fCyt; 5-carboxycytosine, 5-caCyt; base 
excision repair, BER; thymine DNA glycosylase, TDG; 5-hydroxymethylUra, 5-hmUra; 
activation-induced cytosine deaminase (AID); mismatch repair, MMR; deoxyuridine-
triphosphatase; dUTPase; somatic hypermutation, SHM; mismatch repair, MMR; European 
Standards Committee on Oxidative DNA Damage, ESCODD; deoxuynucleosides, dN; 8-
oxoguanine DNA glycosylase 1, OGG1; 8-oxo-7,8-dihydro-2’deoxyguanosine, 8-oxodG; lysine-
specific demethylase 1, LSD1; single-strand-specific monofunctional uracil DNA glycosylase, 
SMUG; acute myeloid leukemia, AML; hematopoietic stem cells, HSC; two-dimensional ultra-
performance liquid chromatography with tandem mass spectrometry, 2D-UPLC-MS/MS. 
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Recently, it was reported that Cyt methylation in cellular DNA is much more dynamic than 
previously thought. It was found that a family of ten-eleven translocation proteins (TET 1, 2 & 
3 enzymes) are responsible for the process of active DNA demethylation (Figure 2). TETs can 
catalyze oxidation of 5-methylCyt (5-mCyt) to form 5-hydroxymethylCyt (5-hmCyt) and the 
oxidation reaction can proceed further to generate 5-formylCyt (5-fCyt) and 5-carboxyCyt (5-
caCyt). 5-fCyt and 5-caCyt may be subsequently recognized and removed by base excision repair 
(BER), via thymine DNA glycosylase (TDG), to complete the process of active DNA 
demethylation (reviewed in Bhutani et al. [2] and Cadet & Wagner [3]). Recently, 5-
hydroxymethylUra (5-hmUra) was shown to be generated also from thymine via a TET catalysed 
reaction [4]. It has been proposed that 5-hmCyt, and perhaps also other modifications, may serve 
as biomarkers of cancer risk [5].  
The aim of this review is to describe the endogenous processes which surround the 
generation, and removal, of the most common types of DNA nucleobase modifications, namely 
8-oxoGua, Ura and certain epigenetic modifications, together with the role of anticancer therapy 
in the generation of these modified DNA nucleobases. 
2. Uracil 
2.1. Sources of Ura in DNA 
2.1.1. Spontaneous Cyt deamination  
Under physiological conditions, spontaneous, hydrolytic deamination of Cyt occurs 
readily, giving rise to Ura. Lindahl estimated that between 100 and 500 Ura residues may occur 
per day in the DNA of a single cell as a result of this process, and that such deamination occurs 
primarily in single-stranded (ss) DNA regions e.g. transcription bubbles or replication forks 
[about 100-fold more rapidly than in double-stranded (ds) DNA] [6]. This finding may explain 
the higher rate of spontaneous Cyt deamination in Saccharomyces cerevisiae compared to 
Escherichia coli, since the slower rate of transcription in Eukaryotes may keep DNA transiently 
in the ss form for a longer period of time [6]. These findings are in a good agreement with in 
vitro studies which demonstrate that Cyt deamination is less likely to occur in dsDNA, than 
ssDNA [6]. 
Another mechanism which may contribute to Cyt deamination in mammalian cells is the 
enzymatic conversion of Cyt in CpG islands to 5-mCyt, catalysed by cytosine-5-
methyltransferase. This reaction starts with a formation of covalent bond with the C6 position of 
Cyt, leading to a transient dihydropyrimidine reaction intermediate that is subject to spontaneous 
deamination. The next step of this reaction is the transfer of methyl group from S-
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adenosylmethionine, acting as a donor, to the Cyt moiety. This kind of enzyme-induced Cyt 
deamination was reported to occur in abortive catalysis by cytosine-5-methyltransferase, or at 
very low concentrations of S-adenosylmethionine [7]. 
 
2.1.2. dUTP misincorporation into DNA 
It is an intrinsic property of replicative polymerases to misincorporate dUTP into DNA 
(both nuclear and mitochondrial) with similar efficiency as dTTP [8], hence the degree of 
misincorporation is likely to depend on their concentrations/ratio in the cellular precursor pool 
(Figure 3). Physiological concentrations of dUTP and dTTP are estimated to be about 0.2 and 37 
µM, respectively. Thus the normal intracellular ratio is well below 1:100. However, in 
differentiated, non-proliferating cells e.g. neurons, quiescent lymphocytes and macrophages, the 
intracellular nucleotide pools may be imbalanced with much higher levels of dUTP (reviewed in 
[9]). Although dUTP is a normal intermediate in thymidylate biosynthesis, its accumulation may 
result in extensive misincorporation into DNA, which generates a substrate for BER via Ura 
DNA glycosylase a.k.a Ura N-glycosylase (UDG and UNG, respectively). Repeated cycles of 
misincorporation and repair increase the likelihood of abasic site formation, and the number of 
DNA strand breaks which, in turn, may lead to cell death. UNG exists in both mitochondrial 
(UNG1) and nuclear (UNG2) isoforms, which are highly specific for Ura, in ss and dsDNA, 
along with 5-fluorouracil, a Ura analogue used in cancer therapy [9]. 
Based on the relative sizes of the dUTP, and dTTP pools it is estimated that about one 
dUTP residue per 104 dTTP is misincorporated into the DNA of every human cell per day [9]. 
Since the dUTP/dTTP ratio is crucial for preventing Ura misincorporation into DNA, dUTPs 
level are strictly regulated, and the enzyme deoxyuridine-triphosphatase (dUTPase) is 
responsible for this task. However, it should be highlighted that the product of the reaction 
catalyzed by dUTPase, namely dUMP, is also a necessary precursor for dTTP synthesis. 
Therefore, the enzyme fulfills a dual role: catalyzing dUTP hydrolysis, and hence preventing Ura 
incorporation into DNA; and delivering dUMP as an essential intermediate for the synthesis of 
the cellular dTTP pool. Reflective of there being both mitochondrial and nuclear dNTP pools, 
dUTPase exists in two isoforms: mitochondrial (cytoplasmic) and nuclear, both encoded for by 
the dut gene [10]. Both isoforms have similar affinities for dUTP, and are largely identical 
differing only in a short region of their NH2 termini, which contains the mitochondria-targeting 
motif. Expression of nuclear dUTPase is proliferation-dependent such that its activity is limited 
mostly in dividing cells. In contrast mitochondrial dUTPase is expressed constitutively, 
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independent of cell cycle status [10]. The presence of nuclear and mitochondrial isoforms of both 
dUTPase and UNG, suggests that excluding Ura from DNA is critical for maintaining the 
integrity of mitochondrial as well as nuclear DNA. 
 
2.1.3. Activation-induced Cyt deaminase (AID) and/or APOBEC deaminases family as a 
source of Ura in DNA 
The discovery that enzymatic deamination of Cyt to Ura in the Ig locus in B cell 
lymphocytes is necessary for antibody diversification after antigen exposure, is only a relatively 
recent event. Activation-induced Cyt deaminase (AID) initiates the process that consequently 
produces substitutions of all four deoxribonucleotides which, in turn, introduces point mutations 
into the variable regions of Ig genes at a rate almost a million times higher than the spontaneous 
mutation rate in somatic cells [11]. This high mutation rate is responsible for the somatic 
hypermutation (SHM) of the Ig genes, and is directly involved in class switch recombination. 
Generally processing of Ura, formed as a result of AID activity, recruits UNG2 and MSH2-
MSH6 from the BER and mismatch repair (MMR) pathways, respectively. It has been proposed 
that there are two distinct phases of SHM; the first depends on the activity of AID, and the second 
phase depends on the mutagenicity of the error prone repair of AID-induced substitutions ([12] 
Figure 4). Phase one occurs when UNG2 removes Ura, formed after AID, and creates an abasic 
site (which has no coding potential) then, in phase two, this abasic site can be filled in with any 
of the four nucleobases. Phase two depends mostly on the error-prone MMR, which recognizes 
an Ura:Gua mispair. A section of the Ura-containing strand is removed, and monoubiquinylated 
PCNA attracts members of a family of low-fidelity translesional DNA polymerases which 
contribute to nucleotide substitutions at an unprecedented level (for a detailed review see [12]). 
One of the most intriguing questions is whether this high level of mutation is selectively 
targeted to specific regions of the antibody genes, or whether it is possible that regions outside 
the Ig locus, or genes other than the Ig genes that are expressed in activated B cells, or indeed 
genes of other cell types, undergo such a rate of mutation. Recent studies demonstrate that AID 
deaminates Cyt moieties in 25% of the genes expressed in mouse germinal centers of B cells 
[11]. However, the mutation rate of these genes is much lower than the Ig loci i.e. for Bcl6 and 
Cd83, mutation frequencies are 20- and 40-fold lower, respectively, and for all the other genes 
about 100-fold lower than the Ig gene [11]. It was also shown that there are two levels of genome 
protection: (i) selective targeting of AID to specific genes, and (ii) the “safety net” of high fidelity 
DNA repair mechanisms which remove Ura generated by AID, just like Ura formed by other 
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processes [11]. Combined, these processes maintain genomic stability and prevent the initiation 
of pathological processes, which have been linked to modified DNA. 
 
2.2. Aberrant AID expression and cancer 
Aberrant AID expression, which can lead to genome-wide mutations in genes other than 
Ig, and in non-lymphoid cells, contribute to the genetic changes which may result in cancer. 
Constitutive AID expression in transgenic mice is responsible for the development of lymphomas 
[13]. These animals also developed tumours in the lung, liver and stomach. Furthermore, a variety 
of human tumours have AID-generated mutations in key oncogenes (i.e. MYC, PIM1, RHOH, 
PAX5) and the tumour suppressor gene p53 [11]. 
It is reported that Helicobacter pylori infection may cause the aberrant expression of AID, 
acting by directly activating proinflamatory cytokines, via the NF-κB pathway which, in turn, 
triggers AID expression [14]. This suggests that AID expression, at least in human gastric 
epithelial cells, is regulated through activation of the NF-κB pathway. Aberrant AID expression 
appears to directly lead to p53 mutations in gastric cancer [14], although the question of “how?” 
remains unanswered. 
Aberrant AID expression has also been described in human B-cell, non-Hodgkin’s 
lymphoma [15], human hepatocellular carcinoma and the non-cancerous liver tissues of patients 
with chronic hepatitis, or liver cirrhosis [16]. More recently elevated expression of APOBEC 
family members, mostly APOBEC3B, was linked with Cyt deamination and Cyt to Ura 
transitions in a multitude of cancers [17,18]. Similarly to AID deamination of Cyt, APOBEC 
enzymes may be responsible for a variety of mutational events [17]. In most cases Ura is removed 
by the UNG/BER pathway, and is replaced faithfully. However, during replication Ura may form 
base pairs with Ade, which in turn results in Cyt to Thy transitions. In some instances after Ura 
is removed, an abasic site is the endpoint, this may cause insertion of any nucleobase opposite, 
since this site is non-instructional (see also section 2.1.3). The abasic site may also be processed 
into further, which may be a source of single- and double-strand breaks, which may lead to 
chromosomal aberration. Notably overexpression of ABOBEC and Ura in DNA are likely major 
source of mutations in multiple of human cancers [17,18]. 
 
2.3. UNG deficiency may lead to carcinogenesis  
8 
 
As mentioned above, recognition of Ura by UNG would normally (other than in Ig genes) 
result in error-free DNA repair, thereby protecting the genome from mutations. However, in 
antibody diversification, the mutation rate is almost a million times higher than the spontaneous 
mutation rate in somatic cells. This results in high levels of repair activity, and subsequent abasic 
site formation, which can lead to in the insertion of a non-instructional nucleobases, and mutation 
fixation, leading to SHM and class switch recombination. Thus, deficiencies in UNG could lead 
to immunological dysregulation or, in the case of AID mis-targeting, the development of B-cell 
lymphomas. Indeed, in UNG-deficient mice, disturbances in antibody diversification occur [19], 
and at three months old these mice develop lymphatic hyperplasia, and in later life have a 22-
fold increase risk of developing B-cell lymphomas [19]. 
It is reported that the genes most frequently targeted by AID (other than the Ig genes) are 
not necessarily those with the highest mutation rate. To address this seemingly contradictory 
finding, an appealing hypothesis has recently been put forward, which suggests that the balance 
between error-prone and high fidelity DNA repair determines the participation of AID-generated 
Ura in carcinogenesis. It is hypothesized that the genome is efficiently protected from AID-
generated mutations not only by targeting the AID, but also by the high fidelity repair of some 
AID-generated Ura moieties. In support of this hypothesis are findings showing that at some 
genes displaying a high frequency of mutations (e.g. Ig or Bcl6), most of the AID-generated Ura 
is repaired via an error prone manner (i.e. MMR), while in the genes where the frequency of 
mutation is lower, high fidelity repair is the predominant mechanism responsible for Ura removal 
[11]. 
 
2.4. The background level of Ura in DNA 
There are several reports concerning the determination of Ura level in DNA which 
substantially differ in their estimates, ranging from 3 x 103 to 4 x 106 Ura moieties per diploid 
genome, i.e. almost three orders of magnitude separate the highest from the lowest estimates 
[17,20]. The very wide variation in estimates of the basal level of this form of modification may 
depend upon cell type used and design of the study. However, as we have seen from the work of 
the European Standards Committee on Oxidative DNA Damage (ESCODD), the analytical 
methods used for quantification may also contribute significantly. 
Background levels of Ura have been determined using different techniques including 
GC/MS and LC/MS [20]. These techniques are combined with the use of UNG to recognise and 
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excise Ura moiety from DNA. This raises the important question of how efficient is this enzyme 
in detecting and removing damage? As noted above, UNG is one of the initiating DNA 
glycosylases of the BER pathway, and is primarily responsible for the recognition and removal 
of Ura. However, it is reported that UNG exhibits a preference for Ura in ssDNA, together with 
Ura:Gua base pairs over Ura:Ade (reviewed in [19]). There are also results demonstrating UNG 
preference for Ura within a particular sequence context [21]. Therefore the use of UNG may not 
release, and hence GC-MS may not detect, all the potential Ura. Enzyme efficiency will also 
depend upon experimental conditions  raising the possibility of inter-assay variation caused by 
differences in enzyme efficacy. 
There are some experimental data which report up to 1 x 104 Ura residues are generated 
in per human genome per day [22], with the authors concluding that this is a realistic background 
level of Ura in DNA. As noted earlier, spontaneous deamination of Cyt should be relatively a 
rare event and enzymatic deamination of Cyt, under physiological conditions, is restricted only 
to the Ig locus in B lymphocytes. However, dUTP, instead of dTTP, can be easily incorporated 
into DNA by polymerases if the cellular ratio of the dTTP/dUTP is too low. Since mammalian 
DNA polymerases do not differentiate between dTTP and dUTP, the background level of Ura in 
DNA may primarily depend on the activity of dUTPase, which regulates the size of the dUTP 
pool, and UNG. Consistent with this, the expression of the nuclear forms of dut and UNG2 are 
cell-cycle regulated with the highest expression during S phase, with low and, in the case of 
dUTPase almost undetectable, levels in differentiated cells [23]. The possibility also exists that, 
if the levels of dUTP are high, then Ura may be reincorporated during repair synthesis, despite 
the efforts of UNG to exclude it from the genome. Recently, using LC-MS/MS-based 
methodology and after exclusion of the most likely factors responsible for potential artifactual 
formation of Ura in DNA (e.g. contamination of reagents with deaminases), the baseline level of 
Ura was estimated to be in the range of 0.056 to 4.03 dU/106 deoxuynucleosides (dN) in cultured 
cells lines [24,25], 1 to 9.6 dU/106 dN in human leukocytes [26], 11.41 dU/106 dN in human 
colorectal cancer tissue and 12.17 dU/106 dN normal colon tissue from the tumour’s margin [27]. 
 
3. 8-Oxo-7,8-dihydroguanine 
3.1. Source and mutagenic potential of 8-oxoGua 
It has been shown that free radical attack upon DNA generates a wide range of DNA 
modifications, among them modified DNA nucleobases. ROS attack of DNA leads to a large 
number of pyrimidine- and purine-derived lesions, and some of these modified DNA nucleobases 
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have considerable potential for downstream effects on the integrity of the genome (reviewed in 
[28]). 
Many oxidatively generated nucleobase lesions are mutagenic, irrespective of whether 
they are formed in situ, or arise by misincorporation from the 2’-deoxyribonucleotide pool. For 
the most part, 8-oxoGua formed in situ results in G→T substitutions, whereas 8-oxo-7,8-dihydro-
2’-deoxyguanosine triphosphate (8-oxodGTP), misincorporated from the oxidised dGTP pool 
opposite dA, produces an A→C substitution. Generally, oxidatively generated DNA nucleobase 
lesions are best described as weakly mutagenic, for example, 8-oxoGua has a mutation frequency 
of 2.5 - 4.8% in mammalian cells, although its propensity for formation, persistence and 
accumulation in vivo could give this value greater significance. Indeed, oxidation events are 
reported to be largely responsible for spontaneous mutagenesis (reviewed in [29]). 
It is clear that, depending upon the lesion in question, one consequence of oxidised 
nucleobases persisting in DNA is mutation. For this reason multiple systems exist to prevent 
lesion formation and, should damage occur, ensure rapid lesion removal. Furthermore, the repair 
enzyme systems possess considerable redundancy in their substrates. Analogous to the processes 
which exclude Ura from DNA, the guanine oxidation, or “GO” system, first describe in E. coli, 
represents a means to prevent the persistence of 8-oxoGua in DNA [30]. The human equivalent 
of the GO system, at its simplest, includes involvement from human 8-oxoGua DNA glycosylase 
1 (hOGG1; BER), human mutY homologue (hMYH; MMR), and human mutT homologue 
(hMTH1, or NUDT1; prevention of misincorporation). Working in concert, these enzyme 
systems remove 8-oxoGua, or native nucleobases mis-paired opposite 8-oxoGua, from genomic 
(nuclear and mitochondrial) DNA; or hydrolyse 8-oxodGTP to 8-oxodGMP in the dGTP pool, 
to prevent misincorporation by DNA polymerases. The products of these repair activities (in 
addition to maintenance of genomic integrity) are 8-oxoGua, unmodified nucleobases (which can 
be salvaged and recycled) and, as we have proposed previously, 8-oxodG [31]. Although it 
appears that the potential exists for these oxidised products to be erroneously reincorporated into 
DNA [32], the majority ultimately appear in the urine where their measurement is used as a well 
established, non-invasive biomarker of oxidative stress [31]. 
 
3.2. Role of oxidatively generated DNA damage in malignant transformation  
DNA oxidation has a potential role in the initiation, promotion and malignant conversion 
(progression) stages of carcinogenesis. Given that cumulative cancer risk increases with the 
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fourth power of age, and is associated with an accumulation of DNA damage, it is reasonable to 
investigate the potential role of oxidatively generated DNA damage in cancer.  
Lesions such as 8-oxoGua are established biomarkers of oxidative stress and, coupled 
with their potential mutagenicity in mammalian cells, this has lead to their proposed potential as 
intermediate markers of a disease endpoint, such as cancer. Supportive of this proposal are the 
findings that GC→TA transversions, potentially derived from 8-oxoGua, have been observed in 
vivo, in the ras oncogene and the p53 tumour suppressor gene in lung and liver cancer. Of course, 
GC→TA transversions are not unique to 8-oxoGua, whereas CC→TT substitutions, in the 
absence of UV light i.e. in internal tumours, have been identified as signature mutations for ROS 
[33]. 
Numerous studies have attempted to establish a relationship between levels of oxidatively 
generated DNA damage and cancer, and we have contributed to this literature. Elevated levels of 
damage are purported to arise as a consequence of an environment in the tumour low in 
antioxidant enzymes, and high in ROS generation, and/or reduced DNA repair [reviewed in [29]]. 
It has been widely demonstrated that the levels of free radical-induced DNA nucleobase 
modifications, including 8-oxoGua, are elevated in human cancerous lung tissues, compared to 
the cancer-free surrounding tissue [34]. Our investigations in benign tumours show that 
oxidatively damaged DNA may be a causative factor in cancer development. Higher levels of 8-
oxoGua are observed in uterine myoma tissues, compared to corresponding tumour-free tissues 
[35]. Uterine myomas are some of the most common gynaecological tumours, and are 
monoclonal in origin, being benign tumours derived from a single mutated myometrial cell. One 
of the factors that may predispose to malignant transformation is the size of the tumour. We 
showed a positive correlation between the tumour size, the amount of 8-oxoGua [35] suggesting 
that higher levels of 8-oxoGua in benign tumours may itself be a risk factor for malignant 
transformation. Furthermore, the increased levels of modified DNA nucleobases may contribute 
to the genetic instability, and the metastatic potential of tumour cells in fully developed cancers. 
Gackowski et al. described a unique study in which a number of markers of oxidatively 
modified DNA were measured in a cohort of non-small cell lung cancer patients (all of which 
were smokers) and two control groups (both control groups were matched to the cancer patients 
for age, but only one also matched for smoking status) [36]. Besides urinary excretion of 8-
oxoGua and 8-oxodG, leukocyte levels of 8-oxoGua were also analysed. The level of 8-oxoGua 
in leukocyte DNA from cancer patients was significantly higher than in either control group. The 
urinary levels of 8-oxoGua and 8-oxodG were similar in both the cancer patients and the control 
group with similar smoking status, suggesting that the higher concentration of 8-oxoGua in lung 
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cancer patients’ leukocytes is a result of a DNA repair defect, most likely in BER. This proposal 
is supported by the measurement of 8-oxoGua DNA glycosylase activity in the leukocytes of 
both smoker groups. Total 8-oxoGua DNA glycosylase activity was lower in the smoking cancer 
patients, compared to the disease-free smokers. Consistent with this, OGG1 knockout mice are 
predisposed to develop lung carcinoma and 8-oxoGua accumulates in their DNA [37]. 
To better understand the role of oxidatively damaged in lung cancer development, three 
DNA damage/repair parameters in non-small cell lung cancer patients were studied: DNA 8-
oxoGua levels; 8-oxoGua glycosylase activity; and 8-oxodGTP hydrolysis activity in tumour and 
surrounding normal lung tissue were compared [38]. Despite 8-oxoGua glycosylase activity 
being lower in tumour than in normal lung tissue, levels of 8-oxoGua were significantly lower in 
tumour than in normal lung tissue. In contrast, 8-oxodGTP hydrolysis activity was higher in the 
tumours, than in normal lung tissue (and three orders of magnitude higher than that of glycosylase 
activity). The results support the suggestion that several different components of the “GO” 
system interact, and contribute to the maintenance of 8-oxoGua levels in human DNA, with the 
greatest contributor appearing to be the removal of 8-oxodGTP from the cellular 2’-
deoxyribonucleotide pool [38]. These early findings have contributed to the foundations for the 
recent intense interest in the enzyme(s) that remove 8-oxodGTP (and other oxidised nucleic acid 
precurors), as a potential therapeutic target (reviewed in [39]). This also raise the possibility that 
urinary 8-oxodG may be used to non-invasively give some indicator of 8-oxodGTPase activity, 
given that global genome nucleotide excision repair and transcription repair have been ruled out 
a sources of this lesion in urine [40]. 
Clearly, alterations in repair activity towards DNA damage have the potential to affect 
lesion levels, and hence outcome. Whether this of significance, in terms of predisposition to 
disease, remains to be established [41]. Taken together, these data suggest that, whilst the role of 
oxidative stress in carcinogenesis appears to be well established, the extent to which oxidatively 
generated DNA damage contributes has not been well defined - with a “black box” separating 
damage initiation (and events such a mutation, microsatellite instability, loss of heterozygosity 
etc) from the development of disease Apart from a few notable exceptions, such as aflatoxin-
induced DNA damage, this appears to be the case for many forms of DNA damage, not just 
oxidatively generated DNA damage.  
Although the precise role for oxidatively generated damage in cancer (or indeed many 
diseases) is not well defined, we propose that oxidatively damaged DNA plays an important role 
in malignant transformation. This is supported by the presence of multiple pathways for its repair, 
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clearly the cell needs to prevent damage persistence. Indeed, there appears to be no limit to the 
number of pathological conditions in which elevated levels of oxidatively damaged DNA have 
been reported [33]. Of course, the mere presence of damage is not proof of a causative link but, 
given the close link between ROS formation and oxidatively generated DNA damage and the 
importance of DNA damage and mutation in carcinogenesis, it is not a large leap of intuition to 
link oxidatively generated DNA lesions and cancer. What is not clear is why elevated levels of 
damage, in some instances, leads to cancer, but in others leads to any one of a wide range on non-
malignant diseases [42]. We propose that perhaps it is not the total levels of damage that is 
important, but the distribution of damage. Recently methodology to map various forms of DNA 
damage across the genome, at varying levels of resolution was described [43,44]. We propose 
that approaches such as these represent a major advance for our understanding of the role of 
oxidatively damaged DNA in disease. 
Taken together, these literature suggests that, whilst the role of oxidative stress in 
carcinogenesis appears well established, the extent to which oxidatively damaged DNA 
contributes is less well defined. Nevertheless, it appears that the DNA damage can be more 
closely associated with initiation events, rather than promotion, and this may be due to the 
potential for a multiplicity of mutagenic lesions to be formed, along with their effects on cell 
function [41], and, as being more recently described, perhaps epigenetic effects [45,46], see 
below. 
 
3.3. Potential regulatory role of 8-oxoGua 
There is no doubt that oxidative stress can lead to cell/tissue injury, via the reaction of 
ROS with biomolecules, and may be responsible for a variety of disparate disease processes. 
Recently researchers have begun to appreciate that some ROS were exploited by natural selection 
to act as mediators of physiological processes. Likewise, several recent reports strongly suggest 
that the presence of 8-oxoGua in DNA may be used as epigenetic factor rather than just inducing 
toxic/mutagenic damage to this macromolecule. Indeed, 8-oxoGua is nontoxic, weakly 
mutagenic and is readily repaired. Moreover, some experimental data demonstrate that a high 
background level of this modification can be tolerated without major consequences for the cell 
[47]. 
There is evidence that demonstrates that 8-oxoGua generation may regulate 
transcriptional activation, derived from experiments involving estrogen-responsive genes, Myc 
targeted genes and hypoxia-inducible genes [48-51]. It was demonstrated that exposure of cells 
to estrogen substantially increases 8-oxoGua in the promoter region of estrogen-responsive 
14 
 
genes, which in turn recruits OGG1 and topoisomerase IIβ. OGG1 generates transient nicks, 
which allows entry of the topoisomerase, the activity of which relaxes the DNA strand, triggering 
chromatin conformational changes essential for estrogen-induced transcription [48]. It has been 
shown that a similar mechanism is responsible for Myc-induced transcription activation [50]. It 
is proposed that upon binding of above mentioned transcription factors to the specific sequences, 
demethylating enzyme lysine-specific demethylase 1 (LSD1) is recruiting. LSD1 is a FAD-
containing enzyme which is responsible for H2O2 production during demethylation process [52]. 
This H2O2 can cause the formation of 8-oxoGua at discrete foci and trigger a series of events, as 
described above, which can lead to transcriptional activation [51]. Recently it was demonstrated 
that generation of 8-oxoGua in G-rich regulatory elements in the promoters of several genes 
(VEGF, TNF-α, SIRT1) is directly linked to an increase transcription through the activation of 
BER pathway (reviewed in Fleming & Burrows [46]. 
We reported an approximately five-fold increase in 8-oxoGua in transcriptionally active 
nuclei compartments (euchromatin and matrix fraction) in comparison to transcriptionally 
silenced heterochromatin [45]. Our data suggest that the presence of 8-oxoGua in specific DNA 
sequences may be widely used for transcription regulation, not just restricted to above reported 
genes, and are in line with the hypothesis which proposes an epigenetic role for 8-oxoGua in 
DNA. This proposed epigenetic regulation by 8-oxoGua would be in contrast to the role of 5-
mCyt, which is responsible for transcription suppression. Interestingly, in our recently published 
study, we demonstrated a negative correlation between background levels of 8-oxoGua and 5-
mCyt in DNA [27]. The mechanisms that underly site-specific DNA modifications, chromatin 
changes, and transcription, are highly complex and may depend on numerous factors, such as 
sequence context, tissue differences or/and specific proteins assembly, to name a few [48,50]. 
Therefore, the context in which 8-oxoGua is present in DNA may be decisive concerning its 
mutagenic or epigenetic potential (see also Fleming & Burrows [46]. Although proposal for the 
involvement of 8-oxoGua in transcription regulation is not universally accepted, it should be 
remembered that the analogous process of iterative oxidation of 5-mCyt and BER, as a simple 
mean of demethylating DNA and activating genes, is well documented [2,53]. 
 
3.4. Steady state levels of 8-oxoGua in cellular DNA 
Historically, a plethora of previous studies have quantified the level of 8-oxoGua in 
cellular DNA, but their results varied considerably. The first trial to standardize the analysis of 
8-oxoGua in DNA was made over twenty years ago by ESCODD. After several trials, along with 
some standardization and refinement of methodology, consensus was achieved between HPLC-
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EC and the comet assay, and the background levels of 8-oxoGua in human leukocytes was 
estimated to be between 0.3 and 4.2 per 106 dG [54], determined as the median of the values 
obtained from a dozen of European laboratories. These values appear to be rather accurate for a 
steady state, and recently reported values remain consistent with those described by the 
ESCODD, e.g. [4,27].  
 
4. Epigenetic effects of modified DNA nucleobases 
4.1. 5-Methylcytosine and their derivatives 
Cyt methylation, usually at CpG dinucleotides, is one of the most important epigenetic 
modifications which has a profound impact on gene expression (silencing gene expression), 
cellular identity, and organismal fate. The reverse of DNA methylation (demethylation) is 
equally important to activate previously silenced genes. Although an accumulation of evidence 
suggests that active demethylation is possible in mammalian cells, its molecular mechanism has 
remained largely enigmatic [for review [2]]. The first discoveries described in two independent 
reports published in Science [55,56] demonstrated that 5-mCyt may be oxidized to 5-hmCyt in 
mammals and, in genomic DNA, may represent 0.003 - 0.6% of all Cyt [53]. After the 
“rediscovery” of 5-hmCyt in 2009, the results of a plethora of studies have confirmed the pivotal 
role of this modification in active DNA demethylation [2,57,58] while a role for the other 
derivatives (see below) is more obscure, not least due to the lack of highly sensitive methods for 
their detection and quantification. 
The most plausible mechanisms for active 5-mCyt demethylation includes the 
involvement of TET proteins in oxidation of 5-mCyt to 5-hmCyt, which can be further oxidized 
to 5-fCyt and 5-caCyt (Figure 2). BER, acting via TDG, replaces 5-fCyt, 5-caCyt with Cyt to 
demethylate DNA [review in [2]]. A second scenario  involves prior deamination of 5-mCyt to 
Thy, which generates a Gua:Thy mis-pair, and is a substrate for TDG (or some other Gua:Thy 
glycosylase). Here, cytidine deaminase of the AID/APOBEC family is implicated in the 
deamination step. It is possible that TDG may act in concert with these deaminases [59]. It is also 
possible that an, as yet unspecified, 5-hmCyt glycosylase is involved in its direct removal, with 
subsequent replacement with an unmodified Cyt [60]. 5-hmCyt could also be deaminated by AID 
to yield 5-hmUra which, in turn, may be removed by TDG or an enzyme from the single-strand-
specific monofunctional uracil DNA glycosylase (SMUG) family (reviewed in [57]).  
It is not clear why, in some instances, the TET enzymes are the major, or only, regulators 
of DNA demethylation. It is also not clear why, in some contexts, 5-hmCyt is the major product 
and in others 5-fCyt and 5-caCyt are formed via iterative oxidation. As mentioned above, 5-
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hmCyt is a key player in the active demethylation process, with some data suggesting that it may 
also play a role in regulation of gene expression.  
 
4.2. Is there a link between active demethylation and malignant transformation? 
It has long been known that DNA hypomethylation occurs in many human cancers and 
precancerous conditions [61]. This has led to the suggestion that the hypomethylation might be 
responsible for enhanced genetic instability and malignant transformation. However, the 
mechanisms of hypomethylation are largely unknown, and hence it is unclear whether this 
epigenetic phenomenon is a cause or consequence of malignant transformation (for a review see 
[62]).  
It has been found that the level of 5-hmCyt is several fold lower in DNA isolated from 
some solid tumours, compared to surrounding normal tissues [63]. It is unclear how or why 5-
hmCyt is decreased in cancer tissues. It is possible that decreased activity of TET proteins may 
be responsible for this phenomenon [64], or 5-hmCyt is lost passively through replication since 
an inverse relationship between 5-hmCyt and 5-fCyt levels and cell proliferation is observed 
[65,66]. It is also possible that active DNA demethylation occurs under different conditions (e.g. 
chronic inflammation). It is noteworthy that both 5-fCyt and 5-caCyt have promutagenic 
properties and may themselves be involved in malignant transformation [67,68].  
As mentioned above, it is proposed that 5-hmCyt could be deaminated by AID (or another 
enzyme from the APOBEC family) to yield 5-hmUra, which is then removed by TDG or SMUG. 
Although there are no firm experimental data which directly prove this assumption, efficient 
removal of 5-hmUra from the genome supports this hypothesis [69]. Interestingly 5-hmUra was 
originally identified as an oxidatively modified DNA nucleobase derivative (a product of 
thymine oxidation). However, the 5-hmUra:Ade base pair generated during this reaction is not 
miscoding [57,69] and does not perturb DNA structure [70]. Indeed, in some bacteriophage, 5-
hmUra completely replaces Thy [71]. Moreover, the 5-hmUra:Ade base pair is poor substrate for 
TDG and SMUG, whereas the 5-hmUra:Gua mispair, which is formed during active 
demethylation, is excised with 60 times greater efficiency, and TDG does not excise 5-hmUra 
when paired with Ade [72]. These results suggest that there is no need for the removal of 5-
hmUra paired with Ade. Therefore, the existence of 5-hmUra glycosylase activity, which very 
quickly and efficiently removes this modification from cellular DNA [57,59,73], suggests that 
the purpose of this activity is to remove 5-hmUra (specifically when paired with Gua), formed 
during oxidation/deamination of 5-mCyt [74].  
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4.3. Current knowledge of the role of 5-hmCyt in tumour development 
Several recent studies show that genomic levels of 5-hmCyt are profoundly decreased in 
many types of human malignancies, compared to matched non-tumour tissue [75,76]. 
Furthermore it has been demonstrated that lower 5-hmCyt levels are an distinctive epigenetic 
indicator of clinical outcome, and correlates with an increased risk of neoplastic progression [75]. 
For example, in the case of human hepatocellular carcinoma, the level of 5-hmCyt correlates with 
tumour stage [77]. It is possible that a decrease in 5-hmCyt levels is due to the decreased 
expression of TETs. Loss-of-function mutations in TET2 have been described in various 
hematological malignancies, including 7% to 10% of acute myeloid leukemia (AML) patients 
[discussed in [78]]. Pronier et al. demonstrated that TET2 knockdown skews human progenitor 
differentiation toward the myeloid lineage, giving an advantage to monocytic development at the 
expense of the granulocytic lineage [79]. The increased prevalence of TET2 mutations in older 
patients with hematological cancers [80], together with association between TET2 mutations and 
age-associated skewing in blood cells, particularly within the myeloid compartment of elderly 
subjects [81], further support an initiating role for TET2 mutation in the pathogenesis of age-
associated hematological cancers. These data, in combination with recent studies in murine 
systems, support a model where TET2 mutations in hematopoietic stem cells (HSC) confer 
enhanced self-renewal and clonal expansion resulting in age-related myeloid lineage bias. 
TET1 and TET3 mutations are very infrequent in hematologic malignancies, with only a 
few TET1 mutations reported in chronic lymphocytic leukemia, AML, and T-cell acute 
lymphoblastic leukemia. Similarly, TET3 mutations are occasionally, but very rarely, identified 
in peripheral T-cell lymphomas and chronic lymphocytic leukemia [reviewed in [82]]. However, 
recent studies indicate that TET1 also retains a crucial regulatory role in the oncogenic 
transformation of hematopoietic cells. Intriguingly, TET1 has contrasting roles in myeloid and 
lymphoid transformation. In mice, TTE1 loss results in aberrant hematopoiesis characterized by 
an augmented repopulating capacity of HSCs, skewed differentiation toward B cell lineage and 
increased frequency of lymphoid-primed multipotent progenitors. TET-deficient, pre-B cells also 
display enhanced serial replating capacity and accumulation of DNA damage, potentially through 
downregulation of genes encoding components of the DNA repair pathways. Using TET1 and 
TET2 double-knockout mice, Zhao et al. showed that TET1 and TET2 are often concomitantly 
downregulated in acute B-lymphocytic leukemia, and that deletion of both Tet1 and Tet2 in mice 
leads to lethal B cell malignancies [83]. Interestingly, TET1 was required for TET2-deletion-
mediated HSC dysregulation and myeloid malignancy [83]. Taken together, the above suggest 
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that a decrease of genomic 5-hmCyt may be diagnostic and prognostic biomarker of many cancer 
types.  
 
4.4. Baseline levels of epigenetic DNA modification 
There are many proteins that specifically recognize the epigenetic DNA products of active 
DNA demethylation. These modifications may control cell identity and, as mentioned above, 
play some role in tumor development [reviewed in Ficz et al. [84]]. Therefore, knowledge of 
their baseline level can provide important information concerning their biological relevance. The 
authors of several studies determined the levels of all possible intermediates of active 
demethylation products [4,27,85-88], but only a few of them used the gold standard technique, 
i.e. stable-isotope-dilution tandem mass spectrometry. This is the most advanced technique used 
for quantitative determination of a wide spectrum of endogenously generated DNA nucleobase 
modifications. In our laboratory, we utilize isotope-dilution automated online two-dimensional 
ultra-performance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS) 
[27]. This allows the direct analysis of certain DNA modifications, following digestion, with high 
precision, and no need for sample enrichment [85], or derivatisation [87]. Our results for brain 
levels of 5-hmCyt were consistent with those of previous studies [53,65,85,86]. However, we 
[27] and others [4] noted that all modifications were present at very low abundance, and 5-fCyt, 
5-caCyt, 5-hmUra, specifically, were several-fold lower than those reported by Liu et al. [85]. 
All abovementioned groups included sample prepurification and concentration in offline mode 
between the chromatography steps and, with the exception of Liu et al. [85], used stable-isotope-
dilution tandem mass spectrometry. Pfaffeneder et al. performed one-dimensional separation 
whereas Gackowski et al. [27] applied automated online two-dimensional separation what gave 
at least several times lower limits of detection. In agreement with previous studies [76,89], 5-
hmCyt levels reported by Gackowski et al. were five-fold lower in colorectal carcinoma tissue in 
comparison with normal tissue taken from the tumour’s margin. Interestingly, 5-fCyt and 5-caCyt 
were also lower in colon carcinoma tissue (ca. 2.5 and 3.5 fold, respectively). 
It is noteworthy that in the majority of studies where 5-hmCyt, (and other epigenetic DNA 
modifications),were assessed, a semi-quantitative approach (immunohistochemistry) was used. 
The authors of these studies admitted that, although this method is easy to conduct, its ability to 
accurately quantify these modifications is rather poor and it may not be able to reliably determine 
very low levels in DNA [76], although the potential for spatial localisation of the modifications 
within the tissue is a strength of this approach. This kind of determination depends mostly on an 
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antibody affinity/specificity towards specific modification. Therefore, for precise, absolute 
quantification we recommend using chromatographic techniques, combined with tandem mass 
spectrometry, involving internal standards labelled with stable isotopes, as a “gold standard” in 
global genome quantification of 5-hmCyt and the other DNA epigenetic modifications [90]. 
5. Anticancer therapy is linked with the alternation of endogenously generated DNA 
nucleobase damage 
5.1. Aberrant Ura incorporation into DNA 
Accumulating evidence suggests that Ura incorporation into DNA contributes to 
cytotoxicity, resulting from the inhibition of thymidylate biosynthesis. Thymidylate biosynthesis 
has a long history of being an important target for several anticancer drugs [e.g. 
fluoropyrimidynes - 5-fluorouracil and 5-fluorodeoxyuridine (Figure 5), and the antifolates e.g. 
methotrexate], and is widely used as a target in the treatment of a broad range of neoplastic 
diseases including head and neck, breast and gastrointestinal cancers. Studies investigating the 
molecular mechanisms of the cytotoxic effects of these chemotherapeutics seem to suggest that 
cell killing is caused by a process called “thymineless death”. During this process the dTTP pool 
is depleted and dUMP pool accumulates and is subsequently phosphorylated to dUTP by the 
action of kinases. As noted above, imbalance between the dTTP and dUTP pools may overwhelm 
cellular dUTPase activity, resulting in extensive mis-incorporation of dUTP into DNA. This will 
result in high levels of UDG-mediated repair [91], with the potential for AP site generation, and 
the increased risk of cell death via double strange brakes formation. Supportive of this are studies 
in S. cerevisiae strains which differed in dUTPase and UNG1 activity. All strains experienced 
dTTP pool depletion during antifolate treatment, but only those in which there was an 
accumulation of dUTP displayed severe cytotoxicity. Moreover, the cells with diminished 
dUTPase activity were particularly sensitive to the treatment, whereas overexpression of the 
dUTPase greatly decreased sensitivity to antifolate [91]. Furthermore, the results of this study 
demonstrated that the inactivation of Ura repair during antifolate treatment has a dramatic effect 
on both cell lethality, as well as a distinct checkpoint response [91]. Deletion or inhibition of 
UNG1 gene product resulted in a short term enhancement of cell viability after the treatment and 
completion of DNA replication with incorporation of Ura instead of Thy. However, the cells 
which arrested in the G2–M phase of cell cycle exhibited delayed toxicity. The authors 
hypothesized that Ura incorporation, instead of Thy, might be signaling the checkpoint [91].  
In another study, the expression pattern of dUTPase in normal and cancerous tissues, and 
the association between the enzyme expression and response to 5-fluoroUra, was examined [10]. 
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According to the authors, nuclear expression of dUTPase in cancer cells may be a prognostic 
marker for resistance to 5-fluorouracil in metastatic colon cancer patients [10]. This study 
suggests that elevated expression of nuclear dUTPase in tumour cells may protect cells from the 
cytotoxic effect of Ura mis-incorporation induced by inhibition of thymidylate metabolism [10]. 
It is also noteworthy that DNA-directed cytotoxicity of chemotherapeutic agents such as 5-
fluorouracil depends not only on dTTP pool depletion, but also may be driven by the efficiency 
of the repair mechanisms such MMR and/or BER [92]. 
 
5.2. Anticancer therapy leads to the formation of oxidatively generated DNA damage – a 
possible involvement of the modified nucleobases in the development of secondary cancers 
Paradoxically many of the agents used in anticancer therapy are responsible for the 
induction of secondary malignancies, in part through the generation of free radicals. There is a 
well established risk associated with developing secondary cancers after chemotherapy and 
radiotherapy [93,94]. Long-lived B and T lymphocytes may serve as a target cells for carcinogens 
including some anticancer drugs and ionizing irradiation. Some nucleobase modifications, if not 
repaired in the lymphocytes, could lead to mutagenesis in critical genes and ultimately to 
secondary cancers. Since free radical induced DNA damage may possess mutagenic properties, 
and may play a role in carcinogenesis, we have examined whether the modalities used in 
anticancer therapy are responsible for the production of typical free radical induced nucleobase 
modifications in the nuclear DNA of lymphocytes in cancer patients who are undergoing 
anticancer therapy. Ionizing radiation is one of the most commonly used therapeutic agents in 
cancer, with approximately half of all cancer patients receiving radiation therapy. The result of 
our studies demonstrate that exposure of cancer patients to therapeutic doses of ionizing radiation 
causes collateral nucleobase modifications in the genomic DNA of their lymphocytes (reviewed 
in [34]. Anthracycline derivatives have been widely used in the treatment of several types of 
human malignancies. The cytotoxicity of these drugs has been attributed to the inhibition of 
topoisomerase II, as well as the intracellular production of free radicals. Using GC-MS, Akman 
et al. showed that ROS production by the redox cycling of the doxorubicin quinone moiety, is 
responsible for DNA nucleobase modification in isolated human DNA [95]. In our work, using 
epirubicin (the analog of doxorubicin presenting a different configuration of the -OH group in 
the C-4 position of the amino-sugar moiety), we observed similar nucleobase modifications in 
DNA isolated from the lymphocytes of cancer patients undergoing chemotherapy [96]. The 
distinct pattern of these modifications suggest the involvement of •OH in their formation. Whilst 
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anticancer therapy causes significant increases in DNA nucleobase modifications, there was a 
broad, inter-patient distribution of levels. This variation may reflect individual differences in 
metabolism and repair capacity, and/or genetic predisposition [34]. For the majority of patients, 
the levels of the nucleobase products returned to pre-exposure levels 24 h after treatment. Similar 
results were observed in the lymphocyte DNA of the patients who were undergoing radiotherapy. 
This decrease in the level of nucleobase products may be an indication of their repair which, in 
the case of some patients whose the level of certain modifications remained high, suggest an 
impairment of the DNA repair capacities [96,97]. 
 
5.3. Azacytidines as drugs with epigenetic effects 
The azacytidines are analogues of cytidine (Figure 5). Those currently used in the clinic 
are: 5-azacytidine (azacytidine) and 5-aza-2’-deoxycytidine (decitabine), and are known 
inhibitors of DNA methylation [98]. They are used for the treatment of AML and 
myelodysplastic syndrome. When given at low doses (2 mg/m2/day for 7 days), 5-aza-2’-
deoxycytidine inhibited promoter-specific as well as global DNA methylation [99]. Using 
hepatocellular cell lines, it was shown that 5-azacytidine can also influence DNA methylation 
status, triggering an active demethylation pathway through activation of TET2 and TET3 proteins 
[100]. More recently it was demonstrated that combination treatment of AML recipient mice with 
5-azacytidine and clinical grade drug AG-221, which inhibits mutant isocitrate dehydrogenase 
and reduce 2-hydroxyglutarate, a potent inhibitor of TETs protein, can effectively revers 
hypermethylation (reviewed in [101]). 
 
6. Conclusions 
Endogenously generated DNA modifications are a consequence of normal cell 
metabolism, but little is known about their levels, in terms of what might be considered a 
“normal”, or a reference range, what changes may reflect a potential decrease or increase in 
cancer risk, and what/how dietary and environmental factors may modulate these levels. 
Recently, some researchers have started to speculate that at least some DNA nucleobase 
modifications might be drivers in natural selection, acting as genetic or epigenetic mediators or 
modulators of physiological processes. Therefore, the assumption that the processes which lead 
to their production should be avoided at any cost, now appears to be misguided. Intriguingly, all 
endogenously generated, modified nucleobases seem to play important cellular regulatory roles, 
for example: 
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(i) Mutagenesis does not seem to be the only effect of 8-oxoGua. While the other effects 
of this compound are still not completely understood, but available evidence suggests that 8-
oxoGua may also affect expression of several genes via chromatin relaxation [48], or the binding 
of transcription factors to gene promotors. Furthermore, the cell type-specific DNA level of this 
modification is suggested to be essential for cellular physiology [49,102]. 
(ii) The immune system of higher organisms has a strategy to use intentionally generated 
Ura for Ig gene diversification. Also, we have suggested [9] that Ura present in DNA (in Ura:Gua 
as well as Ura:Ade mis-pairs) may also perform an, albeit undefined, regulatory role. 
(iii) Oxidatively generated derivatives of 5-mCyt play an important role in active process 
of DNA demethylation and may have specific regulatory functions [103]. 
We note the requirement for reliable identification and quantification of DNA 
adducts/modifications, whether or not endogenously-derived, and that can aid informing on the 
mechanism of their action and biological relevance. Clinical application of such measurements 
needs to be preceded by full assay validation and a better understanding of the exact role played 
by DNA modifications in the disease pathogenesis. Once these prerequisites are satisfied, DNA 
modification measurements may be helpful as a clinical parameter for treatment monitoring, risk 
group identification and development of prevention strategies. Consequently, this knowledge 
could be used for monitoring cancers, and other diseases related to oxidative stress, aberrant 
metabolism and environmental exposure. 
The above clearly demonstrates that, for DNA, the terms “damage” and “modification” 
have different implications for the cell, but what dictates whether the presence of an altered 
nucleobase is defined as damage, or a lesion, or (more benignly) a modification? Ura, mis-
incorporated into DNA, is not damage per se, it is not even a modified nucleobase, unlike 
deaminated Cyt. It is inappropriate and, as a result of its presence, the DNA has been modified.  
8-oxoGua, however, is both a form of damage, and a modification of Gua, and may have both 
potentially benign and detrimental consequences for the cell. Classically, endogenous 
modifications are viewed to be less detrimental to the cell, after all why would a consequence of 
normal metabolism be detrimental to the cell? However, when ROS generation from 
mitochondrial respiration, or redox cycling xenobiotics is considered, the situation becomes less 
clear cut. We propose that these examples should prompt us to rethink the definitions of damage 
etc, not least since applying the most appropriate term seems to be depend upon the local context 
in a DNA sequence, and possible downstream effects. 
It is also puzzling why potentially mutagenic DNA damage, which occurs at a similar 
level in most tissues, may lead to cancers in some, or non-malignant disease in others? What 
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process determines the outcome? Perhaps the epigenetic DNA nucleobase modifications e.g. 5-
hmCyt and the higher order products of TETs, play a role, as these possess considerable inter-
tissue differences in the levels. We suggest that perhaps it is not simply levels of damage, but 
location of damage that is the key factor, requiring a new generation of techniques, evaluating 
DNA at a 2’-deoxyribonucleotide resolution, to better understand the functional consequences of 
modified DNA. 
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Figure legends 
Figure 1. 
Structure and nomenclature of endogenously generated DNA nucleobases modifications, 2’-
deoxyribonucleosides and 2’-deoxyribonucleotides. 
Figure 2 
Cytosine methylation and active demethylation pathway. 5-mCyt, one of the most important 
epigenetic modifications which has a profound impact on gene repression cellular identity and 
organismal fate, is formed in DNA methyltransferase (DNMT) catalysed reaction. The most 
plausible mechanisms of active 5-mCyt demethylation include involvement of ten-eleven 
translocation (TET) proteins in oxidation of 5-mCyt to form 5-hmCyt which can be further 
oxidized to 5-formylcytosine (5-fCyt) and 5-carboxylcytosine (5-caCyt). Then BER pathway is 
active by the involvement of TDG glycosylase to replace the above-described nucleobase 
modifications (5-fCyt, 5-caCyt) with cytosine to demethylate DNA. 5-hmUra may also be 
generated by TET enzymes from thymine as well as to play an important role in active DNA 
demethylation when is generated via deamination pathway. 
 
Figure 3 
Generation of Ura and 8-oxoGua in nuclear and mitochondrial DNA, and the multiple 
mechanisms for preventing their persistence. Prevention of mis-incorporation: dUTPase 
maintains the critical ratio between the dUTP and dTTP pools, whilst also forming dUMP as a 
precursor for dTTP synthesis; 8-oxodGTPases hydrolyse oxidized 8-oxodGTP to 8-oxodGMP. 
BER: Ura glycosylases and MMR remove Ura from DNA; enzymes such as hOGG1 remove 8-
oxoGua, and hMYH removes mis-matched native nucleobases opposite 8-oxoGua, formed 
following mis-incorporation of 8-oxodGTP. Although not illustrated here, separate pre-cursor 
pools feed the nuclear and mitochondrial genomes. 
 
Figure 4 
Mechanisms of mutations generated as a consequence of cytosine deamination. Processing of 
Ura, formed as a result of AID activity, recruits UNG2 and MSH2-MSH6 from the BER and 
mismatch repair (MMR) pathways, respectively. There are two distinct phases of SHM; the first 
depends on the activity of AID, and the second phase depends on the mutagenicity of the error 
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prone repair of AID-induced substitutions. Phase one occurs when UNG2 removes Ura, formed 
after AID, and creates an abasic site (which has no coding potential) then, in phase two, this 
abasic site can be filled in with any of the four nucleobases. Phase two depends mostly on the 
error-prone MMR, which recognizes an Ura:Gua mispair. A section of the Ura-containing strand 
is removed, and monoubiquinylated PCNA attracts members of a family of low-fidelity 
translesional DNA polymerases which contribute to nucleotide substitutions at an unprecedented 
level. 
 
Figure 5 
Nucleosides analogues used as anticancer drugs which may possess ”epigenetic” mechanisms of 
action 
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